Corbus Pharmaceuticals Holdings, Inc. (CRBP) is a publicly traded company in the Unknown sector. Across all available filings, 23 corporate insiders have executed 266 transactions totaling $62.4M, demonstrating a bullish sentiment with $50.7M in net insider flow. The most recent transaction on Feb 3, 2026 involved a sale of 2,415 shares valued at $19.5K.
No significant insider buying has been recorded for CRBP in the recent period.
No significant insider selling has been recorded for CRBP in the recent period.
Based on recent SEC filings, insider sentiment for CRBP is bullish with an Insider Alignment Score of 91/100 and a net flow of $50.7M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at Corbus Pharmaceuticals Holdings, Inc. (CRBP) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 23 insiders are actively trading CRBP stock, having executed 266 transactions in the past 90 days. The most active insider is Bihua Chen (Executive), who has made 25 transactions totaling $32.8M.
Get notified when executives and directors at CRBP file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Feb 3, 2026 | Hodgson Ian | Chief Operating Officer | Sale | 2,415 | $8.09 | $19.5K | C-Suite |
| Feb 3, 2026 | Smethurst Dominic | Chief Medical Officer | Sale | 3,285 | $8.09 | $26.6K | |
| Jan 14, 2026 | Hodgson Ian | Chief Operating Officer | Award | 85,095 | $N/A | $0 | C-Suite |
| Jan 14, 2026 | Hodgson Ian | Chief Operating Officer | Award | 28,365 | $N/A | $0 | C-Suite |
| Jan 14, 2026 | Cohen Yuval | Executive | Award | 150,000 | $N/A | $0 | |
| Jan 14, 2026 | Cohen Yuval | Executive | Award | 50,000 | $N/A | $0 | |
| Jan 14, 2026 | F. Moran Sean | Chief Financial Officer | Award | 84,247 | $N/A | $0 | C-Suite |
| Jan 14, 2026 | F. Moran Sean | Chief Financial Officer | Award | 28,082 | $N/A | $0 | C-Suite |
| Jan 14, 2026 | Smethurst Dominic | Chief Medical Officer | Award | 85,095 | $N/A | $0 | |
| Jan 14, 2026 | Smethurst Dominic | Chief Medical Officer | Award | 28,365 | $N/A | $0 | |
| Dec 11, 2025 | Chen Bihua | Executive | Sale | 30,029 | $11.46 | $344.1K | |
| Oct 27, 2025 | Cohen Yuval | Executive | Option Exercise | 8,973 | $4.26 | $38.2K | |
| Oct 27, 2025 | Cohen Yuval | Executive | Sale | 8,973 | $17.14 | $153.8K | |
| Oct 24, 2025 | F. Moran Sean | Executive | Option Exercise | 12,981 | $4.26 | $55.3K | |
| Oct 24, 2025 | F. Moran Sean | Executive | Sale | 12,981 | $17.02 | $220.9K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 181 | $56.6M | 88.0% |
Sale(S) | 24 | $5.9M | 9.2% |
Exercise(M) | 28 | $1.8M | 2.8% |
Award(A) | 20 | $34.5K | 0.1% |
Gift(G) | 13 | $0 | 0.0% |
Insiders at Corbus Pharmaceuticals Holdings, Inc. are accumulating shares at an accelerated pace. With 23 insiders making 266 transactions totaling $56.6M in purchases versus $5.9M in sales, the net buying activity of $50.7M signals strong executive confidence. Bihua Chen (Executive) leads the buying activity with $32.8M in transactions across all time.